EUVIMEDEUVIMED entdecken
Klinische Studie (Phase I)Open Access · CC BY 4.0

Clinical Proof-of-Concept of a Non-Gene Editing Technology Using miRNA-Based shRNA to Engineer Allogeneic CAR T-Cells

Caroline Lonez iD, Jennifer Bolsée iD, Fanny Huberty, Thuy Nguyen, Céline Jacques-Hespel, Sebastien Anguille iD, Anne Flament, Eytan Breman iD

International Journal of Molecular Sciences · 15.02.2025 · 26 (4) · 1658

DOI: 10.3390/ijms26041658 ↗

Kurz gefasst

Klinische Studie (Phase I) in der Zeitschrift International Journal of Molecular Sciences, online erschienen am 15.02.2025. Verfasst von Caroline Lonez und 7 weiteren Autor:innen. Beteiligte Einrichtung: Celyad Oncology, 1435 Mont-Saint-Guibert, Belgium. Hauptthemen laut MEDLINE: Immunotherapy, Adoptive, MicroRNAs, Multiple Myeloma, Receptors, Chimeric Antigen. Die Arbeit wurde bisher 18-mal zitiert (Crossref) und nennt 34 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Celyad Oncology, Celyad Oncology SA.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

With the success of chimeric antigen receptor (CAR) T-cell therapy in B-cell malignancies, efforts are being made to extend this therapy to other malignancies and broader patient populations. However, limitations associated with the time-consuming and highly personalized manufacturing of autologous CAR T-cells remain. Allogeneic CAR T-cell approaches may overcome these challenges but require further engineering to reduce their alloreactivity. As a means to prevent graft-versus-host disease (GvHD) of allogeneic CAR T-cells, we have selected a micro RNA (miRNA)-based short hairpin RNA (shRNA) targeting CD3ζ which efficiently downregulates the expression of the T-cell receptor (TCR) below detection level. We generated allogeneic anti-B-cell maturation antigen CAR T-cells (CYAD-211) that co-express an anti-CD3ζ miRNA-based shRNA within the CAR construct which efficiently inhibited TCR-mediated signaling in vitro and GvHD in vivo. CYAD-211 was subsequently evaluated in a Phase-I clinical trial (NCT04613557), in patients with relapsed or refractory multiple myeloma. No signs of GvHD were observed despite evidence of engraftment, demonstrating efficient downregulation of the TCR. Our data provide proof of concept that a non-gene-edited technology can generate fully functional allogeneic CAR T-cells, without any signs of GvHD. However, further engineering of the CAR T-cells is needed to improve their persistence and long-term activity.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Immunotherapy, AdoptiveMicroRNAsMultiple MyelomaReceptors, Chimeric AntigenRNA, Small InterferingT-LymphocytesAnimalsFemaleHumansMaleMiceCD3 ComplexGene EditingGraft vs Host DiseaseProof of Concept StudyReceptors, Antigen, T-Cell

Stichwörter der Autor:innen

CAR T-celladoptive therapyallogeneicnon-gene editingshRNA

Substanzen

CD3 ComplexMicroRNAsReceptors, Antigen, T-CellReceptors, Chimeric AntigenRNA, Small Interfering

Autor:innen und Institutionen

  • Celyad Oncology, 1435 Mont-Saint-Guibert, Belgium.
  • Division of Hematology, University Hospital Antwerp (UZ Antwerp), 2650 Antwerp, Belgium.

ORCID-Profile: Caroline Lonez, Jennifer Bolsée, Sebastien Anguille, Eytan Breman

Förderung

  • Celyad Oncology
  • Celyad Oncology SA

Zitieren

APA

Lonez, C., Bolsée, J., Huberty, F., Nguyen, T., Jacques-Hespel, C., Anguille, S., Flament, A., & Breman, E. (2025). Clinical Proof-of-Concept of a Non-Gene Editing Technology Using miRNA-Based shRNA to Engineer Allogeneic CAR T-Cells. International Journal of Molecular Sciences, 26(4), 1658. https://doi.org/10.3390/ijms26041658

Vancouver

Lonez C, Bolsée J, Huberty F, Nguyen T, Jacques-Hespel C, Anguille S, et al. Clinical Proof-of-Concept of a Non-Gene Editing Technology Using miRNA-Based shRNA to Engineer Allogeneic CAR T-Cells. International Journal of Molecular Sciences. 2025;26(4):1658. doi:10.3390/ijms26041658

BibTeX
@article{Lonez2025,
  author = {Lonez, Caroline and Bolsée, Jennifer and Huberty, Fanny and Nguyen, Thuy and Jacques-Hespel, Céline and Anguille, Sebastien and Flament, Anne and Breman, Eytan},
  title = {Clinical Proof-of-Concept of a Non-Gene Editing Technology Using miRNA-Based shRNA to Engineer Allogeneic CAR T-Cells},
  journal = {International Journal of Molecular Sciences},
  year = {2025},
  volume = {26},
  number = {4},
  pages = {1658},
  doi = {10.3390/ijms26041658}
}
Kostenlos starten →